Feedback / Questions
Piqray (alpelisib) - Novartis
Alpelisib: Regulatory submissions for TNBC/HER2+ advance breast cancer in 2023
(Novartis)
-
Dec 6, 2019 -
R&D Day: Regulatory submission for ovarian cancer in 2023; Regulatory submission for 2L/3L HNSCC in 2024
Regulatory
https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf
Dec 6, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious